# Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

> **NCT02353572** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Colorado, Denver** · enrollment: 3 (actual)

## Conditions studied

- Plasma Cell Myeloma
- Plasmacytosis
- Recurrent Plasma Cell Myeloma
- Smoldering Plasma Cell Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **PROCEDURE:** Autologous Transplant

## Key facts

- **NCT ID:** NCT02353572
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Principle investigator left the institution
- **Last updated:** 2015-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02353572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02353572, "Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02353572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*